Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Nektar Therapeutics (NASDAQ: NKTR) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative new medicines in areas of high unmet medical need. Nektar leverages its expertise in polymer chemistry, antibody engineering, and drug design to create novel drug candidates. Their research and development pipeline primarily includes investigational medicines in immunology and oncology, aiming to provide meaningful new therapies to patients. Key programs include rezpegaldesleukin (rezpeg) for autoimmune diseases and NKTR-255, an IL-15 receptor agonist for oncology.
The San Francisco headquarters serves as the central hub for Nektar's corporate operations, primary research and development activities, strategic planning, clinical development, and administrative functions.
Located in a modern biomedical research park, the facility likely includes state-of-the-art laboratories, collaborative workspaces, and advanced research equipment necessary for drug discovery and development.
The work culture at Nektar's HQ is characterized by a strong emphasis on scientific innovation, collaboration among multidisciplinary teams, and a shared commitment to advancing patient care through novel therapeutics. It's a dynamic environment driven by cutting-edge research in a competitive biotech landscape.
Its location in Mission Bay places Nektar within a dense ecosystem of academic research institutions (like UCSF), other biotech and pharmaceutical companies, and venture capital, fostering collaboration and access to talent. This strategic positioning is crucial for innovation and staying at the forefront of biopharmaceutical development.
Nektar Therapeutics' primary physical operations, including R&D, corporate functions, and manufacturing, are based in the United States (San Francisco, CA, and Huntsville, AL). While direct international office presence has been streamlined, Nektar's global reach is evident through its clinical trial operations, which often involve sites and investigators in multiple countries across North America, Europe, and potentially other regions, depending on the specific drug development program. The company also engages in collaborations and licensing agreements that may extend the reach of its technology and products globally.
455 Mission Bay Boulevard South
San Francisco
California
USA
Address: 1112 Church Street NW, Huntsville, AL 35801, USA
The Huntsville location leverages regional strengths in manufacturing and technical expertise. It plays a critical role in Nektar's ability to scale up production of its innovative therapies and ensure quality control.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Nektar Therapeutics' leadership includes:
Nektar Therapeutics has been backed by several prominent investors over the years, including:
Nektar Therapeutics has experienced significant leadership changes in the past 12 months (approx. May 2023 - May 2024), appointing a new Chief Financial Officer, Chief Medical Officer, and Chief Commercial Officer, while seeing departures in the CFO and CMO roles. These changes suggest a period of strategic realignment and team rebuilding.
Discover the tools Nektar Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Nektar Therapeutics most commonly uses the email format of first initial followed by last name. Understanding common email patterns can be useful for professional communication.
[first_initial][last]@nektar.com
Format
jdoe@nektar.com
Example
75%
Success rate
Nektar Therapeutics • May 9, 2024
Nektar Therapeutics announced its financial results for the first quarter of 2024 and provided updates on its clinical pipeline, including progress on rezpegaldesleukin (rezpeg) in atopic dermatitis and alopecia areata, and NKTR-255 in oncology....more
Nektar Therapeutics • April 1, 2024
Nektar shared new preclinical findings for NKTR-255, its IL-15 receptor agonist, at the AACR 2024. The data highlighted NKTR-255's mechanism of action and its potential to enhance anti-tumor immune responses, particularly in combination therapies....more
Nektar Therapeutics • February 20, 2024
Nektar Therapeutics officially named Sandra Gardiner as its Senior Vice President and Chief Financial Officer. Ms. Gardiner had been serving as Interim CFO since November 2023....more
Nektar Therapeutics • January 4, 2024
Nektar announced the dosing of the first patient in a Phase 1b clinical study evaluating NKTR-255 in combination with an anti-PD1 therapy for patients with squamous cell carcinoma of the head and neck who have not previously received checkpoint inhibitor therapy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Nektar Therapeutics, are just a search away.